Get the Stockscreener App
358.15
0.42%
-1.12
Beone Medicines Ltd Adr stock is traded at $358.15, with a volume of 203.93K.
It is down -0.42% in the last 24 hours and up +19.77% over the past month.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
See More
Previous Close:
$359.27
Open:
$355.61
24h Volume:
203.93K
Relative Volume:
0.62
Market Cap:
$40.50B
Revenue:
$5.76B
Net Income/Loss:
$514.49M
P/E Ratio:
79.92
EPS:
4.4813
Net Cash Flow:
$1.10B
1W Performance:
+9.23%
1M Performance:
+19.77%
6M Performance:
+3.27%
1Y Performance:
+24.18%
1-Day Range:
$353.34
$359.79
1-Week Range:
$326.13
$366.99
52-Week Range:
$253.95
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
358.04 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
524.30 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
795.22 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.97 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Outperform |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Barclays | Overweight |
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Generali Investments Management Co LLC Buys Shares of 8,000 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
The Manufacturers Life Insurance Company Trims Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Charles Schwab Trust Co Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines shares gain about 5.5% after robust Q2 results and new Phase 3 trials announcement - Traders Union
BeOne Medicines Q2 Earnings Call Highlights - sharewise.com
BeOne Medicines (NASDAQ:ONC) CFO Sells $361,805.47 in Stock - MarketBeat
Countdown to BeOne Medicines Ltd.Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 1,044 Shares - MarketBeat
65,456 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Bought by Renaissance Technologies LLC - MarketBeat
ADAR1 Capital Management LLC Makes New Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $15,086,671.00 in Stock - MarketBeat
Rokos Capital Management LLP Purchases Shares of 14,335 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BR:B1ME34 Stock Latest News - TipRanks
BeOne Medicines AG (ONC) stock price, news, quote and history - Yahoo Finance Singapore
ONC Stock Quote Price and Forecast - CNN
Siren L.L.C. Has $138.09 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Temasek Holdings Private Ltd Cuts Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Has $14.12 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
SEB Asset Management AB Invests $16.65 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Jennison Associates LLC Purchases 78,027 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Assetmark Inc. Increases Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
AIA Group Ltd Acquires 3,430 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO Sells 145,861 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 11,698 Shares - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 48,520 Shares of Stock - MarketBeat
Candriam S.C.A. Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 664 Shares of Stock - MarketBeat
ETFs Investing in BeOne Medicines Ltd. Sponsored ADR Stocks - TradingView
ONCBeOne Medicines Ltd ADR Options - Finviz
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy - Sahm
49BA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
A1437N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ONC) - TradingView
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 3,410 Shares - MarketBeat
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
Enterprise value to EBITDA forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines (NASDAQ:ONC) Insider Sells $295,558.32 in Stock - MarketBeat
Temasek Holdings Private Ltd Sells 91,877 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Barings LLC Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beone Medicines Ltd Adr Stock (ONC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rosenberg Aaron | Chief Financial Officer |
Aug 03 '26 |
Sale |
312.71 |
1,157 |
361,811 |
0 |
| Lee Chan Henry | SVP, General Counsel |
Jul 30 '26 |
Sale |
323.69 |
1,044 |
337,932 |
0 |
0.77%
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):